SABCS: The Drug Giredestrant Reduces the Risk of Recurrence of Dangerous Breast Cancer

Scientists from the University of California, Los Angeles have developed a new drug, giredestrant, which may significantly reduce the risk of recurrence of early-stage hormone-dependent breast cancer. The study results were presented at the SABCS — the San Antonio Breast Cancer Symposium.

The research focuses on HR-positive, HER2-negative breast cancer — the most common form of the disease, which uses female hormones (estrogens) for growth and therefore often recurs even after treatment.

In a study involving more than four thousand patients, the new drug reduced the likelihood of the tumor returning by about one-third and also lowered the risk of its spread to other organs.

Participants were monitored for nearly three years from the start of treatment until symptoms disappeared. Those taking giredestrant were less likely to discontinue therapy due to side effects compared to those receiving standard hormone medications.

Giredestrant belongs to a new class of drugs that not only block estrogen receptors but also destroy them, depriving cancer cells of a key growth mechanism. Researchers believe that, if confirmed, the results could make this drug the most significant advance in hormone therapy in decades.

Follow NEWS.am Medicine on Facebook and Twitter